ABOUT / PARTNERS
Partnering at pSivida
As a leader in the development of miniaturized, sustained-release drug delivery systems, pSivida has successfully created partnerships with some of the world's leading pharmaceutical companies. pSivida seeks strategic partnerships to accelerate development of our existing product pipeline; to access complimentary research, technology and development capabilities; and to expand our product portfolio. We seek to combine our strengths with other organizations and work collaboratively to develop and commercialize therapeutic products and devices.
Current Partnerships
Bausch & Lomb
pSivida has licensed two FDA approved products and their underlying technologies to Bausch & Lomb Incorporated: Retisert (R) for the treatment of posterior uveitis and Vitrasert (R) for the treatment of AIDS-related cytomegalovirus (CMV) retinitis.
Alimera Sciences
pSivida has licensed certain Medidur™ drug delivery technology to Alimera Sciences, Inc. for the development of ILUVIEN (R) and certain other ophthalmic products. ILUVIEN for the treatment of diabetic macular edema (DME) has completed two Phase III clinical trials and the NDA is currently under review at the FDA.
Pfizer
pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. to develop certain ophthalmic products utilizing our drug delivery technology.
Partnering Opportunities
pSivida's technologies have broad applicability across therapeutic areas. Our powerful and validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. pSivida's intellectual property portfolio consists 180 patents either issued or granted for acceptance, over 150 pending applications and 60 patent families. We evaluate opportunities where we may collaborate with partners to commercialize and/or co-develop therapeutic products utilizing our technology.
For more information regarding partnering with pSivida contact:
businessdevelopment@psivida.com
